ZURICH, July 19, 2010 Today, Novo Nordisk announced thelandmark recruitment of the 60,000th patient in the A1chieve(R) study - anobservational study designed to investigate the effects of modern insulins inthe management of type 2 diabetes.
Spanning 28 countries across 4 continents and involving more than 3300physicians, A1chieve(R) is set to be the world's largest observational studyin insulin therapy.
Approximately 70 percent of the world's 285 million people with diabetesare living in these 28 emerging countries where there is a rising need andinterest to look at differences in physician decisions in the management ofdiabetes.
"Multinational observational studies like A1chieve(R) provide valuableinsights in the way current therapies are applied when it comes to varyingcultural, economic and epidemiological circumstances," said Philip Home,Professor of Diabetes Medicine at Newcastle University England and Chair ofthe A1chieve(R) Global Advisory Board.
In order to mimic the natural secretion of insulin in the body,commercially available insulin preparations are used in different ways(regimens) based on an individual's need and prevailing local practices.However it is important to evaluate these different regimens in a real lifesetting.
"Once completed A1chieve(R) will provide locally relevant information onthe effective use of modern insulins across different regimens. Thisinformation could be further useful to inform and improve the localguidelines on the management of type 2 diabetes" added Professor Home.
Jesper H0iland, Senior Vice President, Novo Nordisk Region InternationalOperations A/S said "The A1chieve(R) study is another major initiativedemonstrating our commitment as leaders in the field of diabetes care. Ourvast experience and unmatched presence in the emerging countries has enabledus to carry out such a unique and large scale research activity of clinicalimportance."
The results of this multinational study will be available in 2011.
Novo Nordisk is a healthcare company and a world leader in diabetes care.In addition, Novo Nordisk has a leading position within areas such ashaemostasis management, growth hormone therapy and hormone replacementtherapy. Novo Nordisk manufactures and markets pharmaceutical products andservices that make a significant difference to patients, the medicalprofession and society. With headquarters in Denmark, Novo Nordisk employsmore than 28,500 employees in 81 countries, and markets its products in 179countries. Novo Nordisk's B shares are listed on the stock exchanges inCopenhagen and London. Its ADRs are listed on the New York Stock Exchangeunder the symbol 'NVO'. For more information, visithttp://www.novonordisk.com.Further information: References 1. Siddharth N. Shah, Leon Litwak, Jihad Haddad, Praful N. Chakkarwar and Issam Hajjaji. The A1chieve(R) study: a 60,000-person, global, prospective, observational study of basal, meal, and biphasic insulin analogs in daily clinical practice. Diabetes Research and Clinical Practice 88S (2010). 2. IDF Diabetes Atlas 4th Edition, International Diabetes Federation, 2009. http://www.diabetesatlas.org.
SOURCE Novo Nordisk